IFP Advisors’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.74K | Sell |
542
-627
| -54% | -$11.9K | ﹤0.01% | 3411 |
|
|
2026
Q1 | $25.4K | Sell |
1,169
-610
| -34% | -$11.8K | ﹤0.01% | 2651 |
|
|
2025
Q4 | $38.3K | Sell |
1,779
-2,965
| -63% | -$62.5K | ﹤0.01% | 2347 |
|
|
2025
Q3 | $91.4K | Buy |
4,744
+71
| +2% | +$1.27K | ﹤0.01% | 1737 |
|
|
2025
Q2 | $84.9K | Buy |
4,673
+2,807
| +150% | +$120K | ﹤0.01% | 1732 |
|
|
2025
Q1 | $119K | Sell |
1,866
-4,985
| -73% | -$525K | ﹤0.01% | 1426 |
|
|
2024
Q4 | $833K | Sell |
6,851
-92
| -1% | -$11.3K | 0.03% | 568 |
|
|
2024
Q3 | $867K | Buy |
6,943
+5,508
| +384% | +$761K | 0.03% | 513 |
|
|
2024
Q2 | $227K | Buy |
1,435
+100
| +7% | +$12.8K | 0.01% | 985 |
|
|
2024
Q1 | $173K | Sell |
1,335
-9
| -0.7% | -$1.1K | 0.01% | 1067 |
|
|
2023
Q4 | $130K | Buy |
1,344
+228
| +20% | +$21.9K | 0.01% | 1146 |
|
|
2023
Q3 | $135K | Sell |
1,116
-4
| -0.4% | -$452 | 0.01% | 1131 |
|
|
2023
Q2 | $128K | Buy |
1,120
+1,114
| +18,567% | +$144K | 0.01% | 1210 |
|
|
2023
Q1 | $575 | Sell |
6
-213
| -97% | -$27.6K | ﹤0.01% | 3168 |
|
|
2022
Q4 | $21K | Hold |
219
| – | – | ﹤0.01% | 2854 |
|
|
2022
Q3 | $21K | Buy |
219
+200
| +1,053% | +$20.2K | ﹤0.01% | 3048 |
|
|
2022
Q2 | $2K | Hold |
19
| – | – | ﹤0.01% | 4182 |
|
|
2022
Q1 | $2K | Sell |
19
-9
| -32% | -$689 | ﹤0.01% | 4180 |
|
|
2021
Q4 | $4K | Hold |
28
| – | – | ﹤0.01% | 2598 |
|
|
2021
Q3 | $4K | Buy |
28
+27
| +2,700% | +$2.08K | ﹤0.01% | 2661 |
|
|
2021
Q2 | $0 | Buy |
+1
| New | +$76 | ﹤0.01% | 3225 |
|
|
2021
Q1 | – | Sell |
-9
| Closed | -$830 | – | 3215 |
|
|
2020
Q4 | $2K | Hold |
9
| – | – | ﹤0.01% | 2661 |
|
|
2020
Q3 | $1K | Hold |
9
| – | – | ﹤0.01% | 2713 |
|
|
2020
Q2 | $1K | Buy |
+9
| New | +$1.23K | ﹤0.01% | 2608 |
|
|
2019
Q4 | – | Sell |
-500
| Closed | -$50.5K | – | 3099 |
|
|
2019
Q3 | $38K | Buy |
+500
| New | +$59K | ﹤0.01% | 1489 |
|
|
2019
Q1 | $2K | Sell |
11
-731
| -99% | -$94K | ﹤0.01% | 2116 |
|
|
2018
Q4 | $80K | Sell |
742
-912
| -55% | -$114K | ﹤0.01% | 1325 |
|
|
2018
Q3 | $267K | Buy |
1,654
+474
| +40% | +$64.8K | 0.01% | 926 |
|
|
2018
Q2 | $156K | Sell |
1,180
-271
| -19% | -$25.6K | 0.01% | 1211 |
|
|
2018
Q1 | $81K | Hold |
1,451
| – | – | ﹤0.01% | 1513 |
|
|
2017
Q4 | $81K | Sell |
1,451
-281
| -16% | -$14.9K | ﹤0.01% | 1527 |
|
|
2017
Q3 | $79K | Buy |
1,732
+212
| +14% | +$8.47K | ﹤0.01% | 1695 |
|
|
2017
Q2 | $51K | Buy |
1,520
+715
| +89% | +$23.3K | ﹤0.01% | 1965 |
|
|
2017
Q1 | $24K | Sell |
805
-616
| -43% | -$19.1K | ﹤0.01% | 2384 |
|
|
2016
Q4 | $39K | Sell |
1,421
-650
| -31% | -$26.1K | ﹤0.01% | 2029 |
|
|
2016
Q3 | $127K | Sell |
2,071
-1,979
| -49% | -$59.8K | 0.01% | 1237 |
|
|
2016
Q2 | $77K | Buy |
4,050
+4,039
| +36,718% | +$74.8K | ﹤0.01% | 1491 |
|
|
2016
Q1 | $2K | Sell |
11
-11,029
| -100% | -$193K | ﹤0.01% | 2113 |
|
|
2015
Q4 | $426K | Buy |
+11,040
| New | +$358K | 0.03% | 540 |
|
Other funds holding SRPT
EAM
IFP Advisors's SRPT Position: Q2 2026 in Review
IFP Advisors reduced its Sarepta Therapeutics (SRPT) stake by 54% in Q2 2026, selling an estimated $11.9K and leaving 542 shares worth $9.74K. The position accounts for ﹤0.01% of the portfolio, ranked #3411.
IFP Advisors first reported a position in SRPT in Q4 2015 and has held it in 39 quarters since. The position peaked at $867K in Q3 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- IFP Advisors held 542 shares of Sarepta Therapeutics worth $9.74K as of Q2 2026.
- IFP Advisors sold 627 Sarepta Therapeutics shares in Q2 2026, an estimated $11.9K.
- Sarepta Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3411 holding.
- IFP Advisors first reported a position in Sarepta Therapeutics in Q4 2015 and has held it in 39 quarters since.
- IFP Advisors's Sarepta Therapeutics position peaked at $867K in Q3 2024.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.